ICAM1 and infection: Based on this finding, and our previous findings that live attenuated RABV vaccine strains infect and activate primary murine and human B cells in-vitro, we hypothesized that a recombinant RABV vaccine vector that expresses and incorporates ICAM-1 into the viral particle would promote infection of B cells, resulting in enhanced B cell activation in-vitro.